Lori A. Kunkel M.D.
Dr. Kunkel has served on our Board since November 2016 and currently serves on the Board of Directors at Loxo Oncology, Inc., HarpoonMaverick Therapeutics, Inc., and Tocagen, Inc. Dr. Kunkel is also a clinical advisor to Amphivena Therapeutics, Inc., Atreca, Inc. and Verastem, Inc. Previously, she served as Chief Medical Officer at Loxo Oncology, Pharmacyclics, ACT, Syndax, and Proteolix (acquired by Onyx), as well as in senior clinical roles at Baxter Healthcare, Chiron, and Genentech, Inc..
Prior to joining the biotechnology industry in 1995, Dr. Kunkel spent ten years in academic/clinical medicine and served as a faculty member in the Division of Hematology/Oncology’s Bone Marrow Transplant Unit at UCLA. She trained in internal medicine at Baylor College of Medicine, hematology at USC and oncology at UCLA, earning board certifications in these specialties. Dr. Kunkel received a B.A. from UCSD and an M.D. from USC.